FDA Inspection 962695 — ImprimisRx CA, Inc., dba ImprimisRx

ImprimisRx CA, Inc., dba ImprimisRx — FEI 3003436217

The FDA completed an inspection of ImprimisRx CA, Inc., dba ImprimisRx on March 14, 2016 in Irvine, CA. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). 8 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Official Action Indicated (OAI) (OAI)
End Date
March 14, 2016
Fiscal Year
2016
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Irvine, CA (United States)

Citations

IDCFRDescription
110521 CFR 211.22(d)Procedures not in writing, fully followed
115921 CFR 211.28(a)Clothing appropriate for duties performed
127421 CFR 211.68(a)Calibration/Inspection/Checking not done
143421 CFR 211.42(c)(10)(iv)Environmental Monitoring System
143521 CFR 211.42(c)(10)(v)Cleaning System
145221 CFR 211.113(b)Validation lacking for sterile drug products
179021 CFR 211.80(b)Handling and Storage to Prevent Contamination
355921 CFR 211.56(a)Sanitation--buildings not clean, free of infestation